THE CORPORATE LIBRARY

Related Party Transactions and Outside Related Director Information

US Oncology, Inc. (Retired) (USON.X)

5/24/2004 10K Information

Dr. Jones, who is one of our directors, is employed by Texas Oncology, P.A. We and Texas Oncology, P.A. are parties to a service agreement pursuant to which we provide Texas Oncology, P.A. with comprehensive management and development services. During 2003, Texas Oncology, P.A. paid us aggregate fees of approximately $389 million pursuant to the service agreement. That fee amount is equal to 33.5% of the earnings before interest and taxes of Texas Oncology, P.A., subject to certain adjustments, plus direct expenses of Texas Oncology, P.A. Dr. Jones also serves as a medical director for us and was paid $172,500 during 2003 in such capacity.

Dr. Schwartz, one of our directors, is president and medical director of Minnesota Oncology Hematology, P.A. ("Minnesota Oncology"). We and Minnesota Oncology entered into a service agreement effective July 1, 1996. During 2003, Minnesota Oncology paid us an aggregate of approximately $5.7 million excluding reimbursement for direct expenses of Minnesota Oncology, pursuant to its service agreement.

On March 20, 2004, we signed an agreement to merge with Oiler Acquisition Corp., an affiliate of Welsh, Carson, Anderson & Stowe IX, L.P. ("WCAS IX"), an investment partnership which owns approximately 14.5% of our common stock. Russell Carson, one of our directors, is a managing member of the general partner of WCAS IX. Under the terms of the merger agreement, holders of our common stock, other than WCAS IX and its affiliates, will receive $15.05 per share in cash for their shares. For a more detailed description of the merger and the merger agreement, please refer to our Current Report on Form 8-K filed with the Securities and Exchange Commission by us on March 22, 2004, which is incorporated herein by reference.

Mr. Mayor is currently of counsel to Andrews & Kurth L.L.P. Andrews & Kurth L.L.P. serves as counsel to US Oncology.

In March 2001, Dr. Everson was appointed Vice Chairman of US Oncology Inc. and was President of from November 1993 until March 2001.

5/21/2003 Proxy Information

Dr. Rogoff, a former director of US Oncology, is a practicing physician with Arizona Oncology Associates, P.C., a physician group managed by us since January 1995. During 2002, Arizona Oncology Associates, P.C. paid us management fees of $5.5 million, excluding reimbursement for direct expenses of that physician group. Dr. Rogoff resigned from the Board in February 2002.

Dr. Jones, who is one of our directors, and Dr. Bailes, who is our Executive Vice President, are employed by Texas Oncology, P.A. We and Texas Oncology, P.A. are parties to a service agreement pursuant to which we provide Texas Oncology, P.A. with comprehensive management and development services. During 2002, Texas Oncology, P.A. paid us aggregate fees of approximately $389 million pursuant to the service agreement. That fee amount is equal to 33.5% of the earnings before interest and taxes of Texas Oncology, P.A., subject to certain adjustments, plus direct expenses of Texas Oncology, P.A. Texas Oncology, P.A. beneficially owns approximately 1.5% of our outstanding common stock. At December 31, 2002, Texas Oncology, P.A. was indebted to us in the aggregate amount of approximately $6.3 million. This indebtedness was incurred when we advanced working capital to Texas Oncology, P.A. for various uses, including the development of new markets and physician salaries and bonuses. This indebtedness bears interest at a rate negotiated by us and Texas Oncology, P.A. that approximates the published prime lending rate (4.25% at December 31, 2002).

Mr. Powell, one of our directors, is the former Chairman of Baylor Health Care System, of which Baylor University Medical Center ("BUMC") is a part. We lease facilities from affiliates of BUMC. Additionally, affiliates of BUMC provide us various services, including telecommunications and maintenance services. In 2002, payments by us to BUMC totaled an aggregate of approximately $3.0 million for these services.

Dr. Schwartz, one of our directors, is president and medical director of Minnesota Oncology Hematology, P.A. ("Minnesota Oncology"). We and Minnesota Oncology entered into a service agreement effective July 1, 1996. During 2002, Minnesota Oncology paid us an aggregate of approximately $5.7 million excluding reimbursement for direct expenses of Minnesota Oncology, pursuant to its service agreement.